Verisante receives approval to sell Aura in Australia
Ticker Symbol: C:VRS Verisante receives approval to sell Aura in Australia Verisante Technology Inc (C:VRS)
Shares Issued 63,688,732
Last Close 12/16/2011 $0.66
Monday December 19 2011 - News Release
Mr. Thomas Braun reports
VERISANTE OBTAINS AUSTRALIAN APPROVAL
Verisante Technology Inc. has received regulatory approval to market and sell the Verisante Aura in Australia.
"After Canadian and European approval earlier this quarter, obtaining Australian approval completes the company's regulatory goals for 2011," said Thomas Braun, president and chief executive officer. "In Australia, access to quick, accurate information to aid skin cancer diagnoses is absolutely essential."
According to the Australian Government Department of Health, Australia has the highest skin cancer incidence rate in the world, at nearly four times the rates in Canada, the US and the UK. And thirteen times the global average. Australians are also four times more likely to develop a skin cancer than any other form of cancer, and approximately two in three Australians will be diagnosed with skin cancer before the age of 70.Furthermore, general practitioners (GP) in Australia have more than 1 million patient consultations per year for skin cancer. GP consultations to treat non-melanoma skin cancer increased by 14% between 1998-2000 and 2005-2007 - from around 836,500 to 950,000 visits each year, or more than 2,000 skin cancer patient visits per day.Verisante Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96 per cent of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best results for patients.Aura(TM) is a non-invasive optical system designed as a tool to aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds. The device uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The Aura(TM) will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
© 2011 Canjex Publishing Ltd. |
